Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MSC-EV in ACLF After Liver Transplantation
NCT05881668Phase 1Withdrawn
- Sponsor
- The Third Affiliated Hospital of Sun Yat-sen University
- Start
- Sep 2023
- Primary completion
- Sep 2024
- Modality
- Lipid-based Nanoparticles, Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of mesenchymal stem cell-derived extracellular vesicles in acute-on-chronic liver failure (ACLF) (2 arms), sponsored by The Third Affiliated Hospital of Sun Yat-sen University. Primary endpoints: MSC-EV infusion-related toxicity at 24 hours, Aspartate aminotransferase at 6 months and 5 more. Planned start Sep 2023; status: withdrawn.
02
Drugs
mesenchymal stem cell-derived extracellular vesicles
03
Conditions
acute-on-chronic liver failure (ACLF)
Beyond the preview
Go deeper on NCT05881668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05881668.